Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BTI320 is a proprietary, chewable oral formulation composed of fractionated mannan polysaccharides (galactomannan-α and -β) derived from legume seeds. It acts as a non-systemic inhibitor of carbohydrate-hydrolyzing enzymes in the gastrointestinal tract—including alpha-glucosidase, amylase, maltase-glucoamylase, sucrase, and lactase—thereby reducing the breakdown and absorption of complex carbohydrates into glucose. This mechanism attenuates postprandial (after-meal) blood glucose excursions without causing hypoglycemia. BTI320 has been studied for use in type 2 diabetes mellitus and prediabetes to help manage blood sugar levels as an adjunct to lifestyle modification or other therapies. It is available over-the-counter as a dietary supplement under the brand name Sugardown[1][3][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BTI320.